Novel Mutation Detection Test Bio-Rad Laboratories launched a novel multiplex mutation detection test for mutations in the ESR-1 gene related to breast cancer. This product innovation presents a sales opportunity for targeting healthcare institutions and research centers focusing on oncology.

Recent Investment Roubaix Capital LLC made a significant investment of $4.05 million in Bio-Rad Laboratories. This financial backing provides potential for expanding sales efforts and developing new products or solutions that could attract investors looking to partner with a growing biotechnology company.

Product Portfolio Expansion Bio-Rad Laboratories introduced StarBright Red Dyes and GraftAssure, expanding its product portfolio. Sales representatives can leverage these new offerings to engage existing customers for upselling and cross-selling opportunities, as well as target new clients in the life sciences and clinical diagnostics sectors.

Collaboration with Oncocyte The partnership with Oncocyte for developing transplant monitoring products using Bio-Rad's technology signifies a sales potential in the precision diagnostics market. Sales development professionals can explore this collaboration to reach out to medical facilities and transplant centers seeking advanced monitoring solutions.

Global Launch Strategy Bio-Rad Laboratories partnered with Oncocyte for the global launch of the GraftAssure assay. This collaboration opens up sales opportunities on an international scale, allowing sales teams to target regions where precision diagnostics and organ transplant monitoring are in high demand.